Trial · NCT05583526
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 38
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52 | Week 52 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Primary | Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 | Week 52 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Primary | Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalities | Baseline through Week 52 | Safety and tolerability of ritlecitinib in participants with nonsegmental vitiligo |
| Secondary | US-Only: Response based on F-VASI75 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline |
| Secondary | US-Only: Response based on T-VASI50 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Secondary | US-Only: Response based on T-VASI75 at 52 weeks | Week 52 | Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
| Secondary | US-Only: Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Secondary | US-Only: Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Secondary | US-Only: Patient Global Impression of Severity-Face (PGIS-F) | Week 52 | Proportion of responders based on PGIS-F at 52 weeks |
| Secondary | US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) | Week 52 | Proportion of responders based on PGIS-V at 52 weeks |
| Secondary | Global (Other than US): Response based on F-VASI75 at 24 and 36 weeks | Weeks 24 and 36 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Secondary | Global (Other Than US): Response based on T-VASI50 at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Secondary | Global (Other than US): Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Secondary | Global (Other than US): Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks | Weeks 24, 36, and 52 | Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo |
| Secondary | Global (Other than US): Patient Global Impression of Severity-Face (PGIS-F) | Weeks 24, 36, and 52 | Proportion of responders based on PGIS-F at 24, 36, and 52 weeks |
| Secondary | Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V) | Weeks 24, 36, and 52 | Proportion of responders based on PGIS-V at 24, 36, and 52 weeks |
| Secondary | All Countries: Proportion of participants achieving disease stabilization | Baseline through week 52 | The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD compared to placebo |
| Secondary | Response based on T-VASI50 | Baseline through week 4, week 8, week 12, week 48 | Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline) |
| Secondary | Response based on F-VASI75 | Baseline through week 4, week 8, week 12, week 48 | Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) |
| Secondary | Response based on T-VASI75 | Baseline through week 4, week 8, week 12, week 24, week 36, week 48 | Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05583526/registered